Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension.
- DOI
- 10.1016/j.msard.2026.107921
- Published
- 2026-09-11
- Container
- Mult Scler Relat Disord
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.msard.2026.107921,
title = {Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension.},
author = {Pulukuri N and Alva S and Pandit L and Agasti N and Vegda M and Chinni L and Kadri Y and Alexander L.},
year = {2026},
journal = {Mult Scler Relat Disord},
doi = {10.1016/j.msard.2026.107921},
url = {https://doi.org/10.1016/j.msard.2026.107921}
}RIS
TY - JOUR TI - Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension. AU - Pulukuri N AU - Alva S AU - Pandit L AU - Agasti N AU - Vegda M AU - Chinni L AU - Kadri Y AU - Alexander L. PY - 2026 JO - Mult Scler Relat Disord DO - 10.1016/j.msard.2026.107921 UR - https://doi.org/10.1016/j.msard.2026.107921 ER -
APA
N, P., S, A., L, P., N, A., M, V., L, C., Y, K., & L., A. (2026). Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension.. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2026.107921
Source records
- europe-pmc · retrieved 2026-09-26T07:37:29.422Z